<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="909">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452617</url>
  </required_header>
  <id_info>
    <org_study_id>REA-03-2020</org_study_id>
    <nct_id>NCT04452617</nct_id>
  </id_info>
  <brief_title>Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19</brief_title>
  <official_title>Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Mutualiste Montsouris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hydroxychloroquine and azithromycin have been proposed as treatment of COVID-19 patients, but
      few reports have assessed this combination therapy in critically ill COVID-19 patients.

      Many raised concerns regarding the potential cardiac toxicity of this association.

      The purpose of this monocenter retrospective observational study is to evaluate the safety of
      a short term treatment with hydroxychloroquine and azithromycin in critically ill patients
      admitted in ICU for severe COVID-19 with respiratory failure.

      The main objective is to assess the incidence of severe cardiac arrhythmia e.g torsade de
      pointes and cardiac arrest or sudden death, during the treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death</measure>
    <time_frame>30 days after admission in ICU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment of QTc interval prolongation during the treatment period compared to baseline ECG</measure>
    <time_frame>daily</time_frame>
    <description>QTc (corrected QT interval) &gt; 500 ms and Î”QTc &gt; 60 ms</description>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients admitted in ICU for severe COVID-19 with respiratory failure and a
        short term treatment with hydroxychloroquine (HCQ) and azithromycin (AZ):

          -  HCQ administered at a daily dosage of 600mg in 3 doses for 10 days.

          -  AZ administered at a dosage of 500mg on the first day and then 250mg/day for 4 to 6
             days.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  critically ill patients admitted in ICU for severe COVID-19 with respiratory failure
             for at least two days of treatment with hydroxychloroquine and azithromycin.

        Exclusion Criteria:

          -  cardiac conduction disorders

          -  continuous anti-arrhythmic therapy

          -  heart failure

          -  chronic renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyes KNANI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Mutualiste Montsouris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hydroxychloroquine</keyword>
  <keyword>ADRS</keyword>
  <keyword>azithromycine</keyword>
  <keyword>torsade de pointe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

